ArticleScience translational medicine2021
The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 49 citations in OpenAlex.
- Dual plasmepsin IX and X inhibitors are refractory to development of resistance.PLoS pathogens · 2026Article
- The ATM Kinase Inhibitor AZD0156 Is a Potent Inhibitor of Plasmodium Phosphatidylinositol 4-Kinase (PI4Kβ) and Is an Attractive Candidate for Medicinal Chemistry Optimization Against Malaria.Angewandte Chemie (International ed. in English) · 2025Article
- Towards next-generation treatment options to combat Plasmodium falciparum malaria.Nature reviews. Microbiology · 2025Review
- The possibilities and challenges associated with selective targetingTransactions of the Royal Society of South Africa. Royal Society of South Africa · 2025Article
- Targeting Malaria's Achilles' Heels: A Review of Plasmodium Life Cycle Vulnerabilities for Drug Discovery.Current topics in medicinal chemistry · 2025Review
- Innovations in Antimalarial Drug Discovery: New Targets and Leads.Current drug targets · 2025Review
- Accelerating Antimalarial Drug Discovery with a New High-Throughput Screen for Fast-Killing Compounds.ACS infectious diseases · 2024Article
- Inhibitors of malaria parasite cyclic nucleotide phosphodiesterases block asexual blood-stage development and mosquito transmission.Science advances · 2024Article
- Eliminating malaria transmission requires targeting immature and mature gametocytes through lipoidal uptake of antimalarials.Nature communications · 2024Article
- Mixed alkyl/aryl phosphonates identify metabolic serine hydrolases as antimalarial targets.Cell chemical biology · 2024Article
- Aminopyridines in the development of drug candidates against protozoan neglected tropical diseases.Future medicinal chemistry · 2024Review
- Defining the next generation of severe malaria treatment: a target product profile.Malaria journal · 2024Review
- tRNA modification reprogramming contributes to artemisinin resistance in Plasmodium falciparum.Nature microbiology · 2024Article
- Reaction hijacking inhibition of Plasmodium falciparum asparagine tRNA synthetase.Nature communications · 2024Article
- Mixed Alkyl/Aryl Phosphonates Identify Metabolic Serine Hydrolases as Antimalarial Targets.bioRxiv : the preprint server for biology · 2024Article
- Molecular mechanisms of mitochondria-mediated ferroptosis: a potential target for antimalarial interventions.Frontiers in cell and developmental biology · 2024Review
- Simultaneous adjunctive treatment of malaria and its coevolved genetic disorder sickle cell anemia.Blood advances · 2023Article
- Antimalarial drug discovery: progress and approaches.Nature reviews. Drug discovery · 2023Review
- A focus on sustainable method development for greener synthesis.Chemical science · 2023Article
- Predicting Optimal Antimalarial Drug Combinations from a Standardized Plasmodium falciparum Humanized Mouse Model.Antimicrobial agents and chemotherapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
55 authors at 15 institutions in 10 countries.
James M MurithiDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0003-0741-8461
Cécile PascalSanofi, Infectious Diseases Therapeutic Area, Marcy l'Etoile, France.ORCID 0000-0002-2917-6558
Jade BathDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.
Xavier BoulencSanofi Pasteur, Marcy L'Etoile, France.ORCID 0000-0001-7991-3571
Nina F GnädigDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0002-8104-7032
Charisse Flerida A PasajeDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-9780-3680
Kelly RubianoDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0002-4149-4030
Tomas YeoDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0003-2923-6060
Sachel MokDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0002-9605-0154
Sylvie KlieberSanofi R&D, Translational Medicine & Early Development, Montpellier, France.ORCID 0000-0002-3044-0643
Paul DesertSanofi Pasteur, Marcy L'Etoile, France.ORCID 0000-0001-6012-8928
María Belén Jiménez-DíazThe Art of Discovery, Bizkaia, Basque Country, Spain.ORCID 0000-0002-1788-4514
Jutta MarfurtGlobal and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Australia.ORCID 0000-0002-3846-0825
Mélanie RouillierMedicines for Malaria Venture, Geneva, Switzerland.ORCID 0000-0001-7028-764X
Mohammed H Cherkaoui-RbatiMedicines for Malaria Venture, Geneva, Switzerland.ORCID 0000-0001-9630-3863
Nathalie GobeauMedicines for Malaria Venture, Geneva, Switzerland.
Sergio WittlinDepartment of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland.
Anne-Catrin UhlemannDivision of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0002-9798-4768
Ric N PriceGlobal and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Australia.ORCID 0000-0003-2000-2874
Grennady WirjanataGlobal and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Australia.ORCID 0000-0002-6858-8547
Rintis NoviyantiEijkman Institute for Molecular Biology, Jakarta, Indonesia.
Patrick TumwebazeInfectious Diseases Research Collaboration, Kampala, Uganda.
Roland A CooperDepartment of Natural Sciences and Mathematics, Dominican University of California, San Rafael, CA, USA.
Philip J RosenthalDepartment of Medicine, University of California, San Francisco, CA, USA.ORCID 0000-0002-7953-7622
Laura M SanzGlobal Health Pharma Research Unit, GSK, Tres Cantos, Madrid, Spain.
Francisco Javier GamoGlobal Health Pharma Research Unit, GSK, Tres Cantos, Madrid, Spain.ORCID 0000-0002-1854-2882
Jayan JosephSyngene International Ltd., Bangalore, India.ORCID 0000-0002-0095-4213
Shivendra SinghSyngene International Ltd., Bangalore, India.
Sridevi BashyamSyngene International Ltd., Bangalore, India.
Jean Michel AugereauSanofi, Infectious Diseases Therapeutic Area, Marcy l'Etoile, France.
Elie GiraudSanofi, Infectious Diseases Therapeutic Area, Marcy l'Etoile, France.
Tanguy BozecSanofi, Infectious Diseases Therapeutic Area, Marcy l'Etoile, France.
Thierry VermatSanofi, Infectious Diseases Therapeutic Area, Marcy l'Etoile, France.ORCID 0000-0002-1958-235X
Gilles TuffalSanofi R&D, Translational Medicine & Early Development, Montpellier, France.ORCID 0000-0002-9858-8628
Jean-Michel GuillonSanofi, Infectious Diseases Therapeutic Area, Marcy l'Etoile, France.
Jérôme MenegottoSanofi, Infectious Diseases Therapeutic Area, Marcy l'Etoile, France.
Laurent SalléSanofi R&D, Translational Medicine & Early Development, Montpellier, France.ORCID 0000-0003-0069-2951
Guillaume LouitSanofi, Vitry-sur-Seine, France.ORCID 0000-0003-4379-6611
Marie-José CabanisSanofi R&D, Translational Medicine & Early Development, Montpellier, France.ORCID 0000-0003-1238-0584
Marie Françoise NicolasSanofi, Vitry-sur-Seine, France.ORCID 0000-0001-6318-5960
Michel DoubovetzkySanofi, Infectious Diseases Therapeutic Area, Marcy l'Etoile, France.
Rita MerinoSanofi, Infectious Diseases Therapeutic Area, Marcy l'Etoile, France.
Nadir BessilaSanofi, Infectious Diseases Therapeutic Area, Marcy l'Etoile, France.ORCID 0000-0002-5550-034X
Iñigo Angulo-BarturenThe Art of Discovery, Bizkaia, Basque Country, Spain.ORCID 0000-0002-8800-8132
Delphine BaudMedicines for Malaria Venture, Geneva, Switzerland.
Lidiya BebrevskaMedicines for Malaria Venture, Geneva, Switzerland.
Fanny EscudiéMedicines for Malaria Venture, Geneva, Switzerland.ORCID 0000-0002-9177-9755
Jacquin C NilesDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-6250-8796
Benjamin BlascoMedicines for Malaria Venture, Geneva, Switzerland.ORCID 0000-0002-1485-7887
Simon CampbellMedicines for Malaria Venture, Geneva, Switzerland.
Gilles CourtemancheBioaster, Paris, France.ORCID 0000-0002-4887-9961
Laurent FraisseSanofi, Infectious Diseases Therapeutic Area, Marcy l'Etoile, France.ORCID 0000-0002-1530-3894
Alain PelletSanofi, Infectious Diseases Therapeutic Area, Marcy l'Etoile, France.
David A FidockDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA. df2260@cumc.columbia.edu leroyd@mmv.org.ORCID 0000-0001-6753-8938
Didier LeroyMedicines for Malaria Venture, Geneva, Switzerland. df2260@cumc.columbia.edu leroyd@mmv.org.ORCID 0000-0002-5594-3204
Sanofi (France) · FRMedicines for Malaria Venture · CHColumbia University Irving Medical Center · USSyngene International (India) · INCharles Darwin University · AUEuskadiko Parke Teknologikoa · ESGlaxoSmithKline (France) · FRMassachusetts Institute of Technology · USBIOASTER · FRDominican University of California · USEijkman Institute for Molecular Biology · IDInfectious Diseases Research Collaboration · UGMahidol University · THSwiss Tropical and Public Health Institute · CHUniversity of California, San Francisco · US
Funding
TRAINING GRANTS IN ENVIROMENTAL TOXICOLOGYT32ES007020 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ESSIGMANN, JOHN M · 1985 to 2024
$13.1MMechanisms of varied sensitivity of P. falciparum field isolates to the antimalarial drug pipelineR01AI139179 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Philip Jon Rosenthal · 2018 to 2026
$6.3MDefining P. falciparum resistance to artemisinin-based combination therapiesR01AI109023 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FIDOCK, DAVID A · 2014 to 2025
$4.4MElucidating the molecular basis of piperaquine resistance in Plasmodium falciparumR01AI124678 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI David A Fidock · 2016 to 2026
$4.3MNIAID NIH HHS R01 AI109023NIAID NIH HHS R01 AI124678NIAID NIH HHS R01 AI139179NIEHS NIH HHS T32 ES007020Wellcome Trust 200909/Z/16/Z
Abstract
The emergence and spread of
Indexed as
AntimalarialsMalariaMalaria, FalciparumParasitesAnimalsEndocytosisPlasmodium falciparumAntimalarials
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.